The Olink Reveal technology is based on antibodies tagged with a unique DNA code that recognize and bind to specific proteins, and these DNA codes can then be read very accurately using Next-Generation Sequencing. The analysis can be performed on several different sample types, but is primarily used on plasma or serum, making it directly applicable in clinical studies and in material from existing biobanks. The analyses enable clinical researchers to go deeper in their questions and link symptoms and clinical outcomes to underlying biological mechanisms.
The method is expected to strengthen opportunities for advanced medical research in the region. In the long term, this can contribute to identifying new treatment targets and developing more individualized care, which strengthens the region's position as a modern and competitive clinical research environment. Relatively few clinical research environments in Sweden offer this type of high-multiplex proteomics locally, and regionally, it means a further strengthening of operations at the forefront.
At the Clinical Research Center, there is coordinated handling of inquiries regarding the research support offered at the operations, and an easy way in is for researchers to contact via the functional email for clinical research.